KR20220120646A - 만성 전립선염/만성 골반통 증후군의 예방 및/또는 치료제 - Google Patents

만성 전립선염/만성 골반통 증후군의 예방 및/또는 치료제 Download PDF

Info

Publication number
KR20220120646A
KR20220120646A KR1020227025732A KR20227025732A KR20220120646A KR 20220120646 A KR20220120646 A KR 20220120646A KR 1020227025732 A KR1020227025732 A KR 1020227025732A KR 20227025732 A KR20227025732 A KR 20227025732A KR 20220120646 A KR20220120646 A KR 20220120646A
Authority
KR
South Korea
Prior art keywords
amino
carbonyl
benzimidazole
carboxamide
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227025732A
Other languages
English (en)
Korean (ko)
Inventor
겐 오카모토
마키 구리타
히로시 야마구치
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR20220120646A publication Critical patent/KR20220120646A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020227025732A 2019-12-25 2020-12-24 만성 전립선염/만성 골반통 증후군의 예방 및/또는 치료제 Pending KR20220120646A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-233865 2019-12-25
JP2019233865 2019-12-25
PCT/JP2020/048479 WO2021132472A1 (ja) 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Publications (1)

Publication Number Publication Date
KR20220120646A true KR20220120646A (ko) 2022-08-30

Family

ID=76575232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025732A Pending KR20220120646A (ko) 2019-12-25 2020-12-24 만성 전립선염/만성 골반통 증후군의 예방 및/또는 치료제

Country Status (16)

Country Link
US (1) US12599589B2 (https=)
EP (1) EP4082573A4 (https=)
JP (3) JP7499789B2 (https=)
KR (1) KR20220120646A (https=)
CN (2) CN119303087A (https=)
AU (1) AU2020413313B2 (https=)
BR (1) BR112022012485A2 (https=)
CA (1) CA3165891A1 (https=)
CO (1) CO2022010343A2 (https=)
EC (1) ECSP22058286A (https=)
IL (1) IL294191A (https=)
MX (1) MX2022007936A (https=)
PE (1) PE20230164A1 (https=)
PH (1) PH12022551578A1 (https=)
UA (1) UA130283C2 (https=)
WO (1) WO2021132472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082247B (zh) * 2023-01-19 2025-08-01 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN121401398A (zh) * 2025-12-29 2026-01-27 汕头市中心医院 一种实验性自身免疫性前列腺炎大鼠模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
WO2013024898A1 (ja) 2011-08-18 2013-02-21 日本新薬株式会社 ヘテロ環誘導体及び医薬
WO2017073709A1 (ja) 2015-10-29 2017-05-04 あすか製薬株式会社 ピリミジン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011048004A1 (en) * 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
WO2013024898A1 (ja) 2011-08-18 2013-02-21 日本新薬株式会社 ヘテロ環誘導体及び医薬
WO2017073709A1 (ja) 2015-10-29 2017-05-04 あすか製薬株式会社 ピリミジン誘導体

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun., 2002, 291, 884-889
Cancer Res., 2008, 68(9), 3251-3259
Int. J. Urol. 2001 Sep;8(9):495-499
J. Biol. Chem., 2000, 275, 32775-32782
J. Biol. Chem., 2003, 278(21), 19396-19405
j. phymed. 2019, 60, 152987
J. Urol. 2008 May;179(5):1857-1862.
Jakobsson 등, Proc. Natl. Acad. Sci. USA, 1999, 96, 7220-7225
JAMA. 1999 Jul. 21;282(3):236-7.
Oncogene, 2012, 31(24), 2943-2952

Also Published As

Publication number Publication date
ECSP22058286A (es) 2022-09-30
JP2024103724A (ja) 2024-08-01
JP2026015542A (ja) 2026-01-29
MX2022007936A (es) 2022-10-27
PE20230164A1 (es) 2023-02-01
CA3165891A1 (en) 2021-07-01
BR112022012485A2 (pt) 2022-09-06
AU2020413313B2 (en) 2025-11-27
EP4082573A4 (en) 2024-01-10
JPWO2021132472A1 (https=) 2021-07-01
NZ789736A (en) 2025-10-31
CO2022010343A2 (es) 2022-10-31
JP7779953B2 (ja) 2025-12-03
US12599589B2 (en) 2026-04-14
US20230094705A1 (en) 2023-03-30
CN114867495A (zh) 2022-08-05
AU2020413313A1 (en) 2022-07-14
JP7499789B2 (ja) 2024-06-14
PH12022551578A1 (en) 2023-11-29
WO2021132472A1 (ja) 2021-07-01
EP4082573A1 (en) 2022-11-02
CN119303087A (zh) 2025-01-14
UA130283C2 (uk) 2026-01-07
CN114867495B (zh) 2024-10-18
IL294191A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
JP7779953B2 (ja) 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
KR102155559B1 (ko) 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제
US20050009876A1 (en) Indazole compounds, compositions thereof and methods of treatment therewith
JP2011506560A (ja) Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
KR20100101056A (ko) 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
US20120142732A1 (en) Heteroaryls and uses thereof
JP2025182108A (ja) 免疫チェックポイント阻害剤と併用で用いる抗腫瘍薬
RU2836236C1 (ru) Профилактическое и/или терапевтическое средство против хронического простатита/синдрома хронической тазовой боли
WO2025090727A1 (en) Compounds that mediate protein degradation and methods of use thereof
HK40081072A (en) Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
RU2842861C1 (ru) Противоопухолевое средство для применения в комбинации с ингибитором иммунных контрольных точек
RU2780168C1 (ru) Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше
EA043328B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
HK1191936B (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902